CombiMatrix and Prisma Expand Relationship in China, Taiwan, and Other Countries

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--April 28, 2006--Acacia Research Corporation (Nasdaq:CBMX) (Nasdaq:ACTG) announced today that its CombiMatrix group has entered a distribution and manufacturing agreement with Prisma Biotech Corporation. In this relationship, Prisma will promote and sell CombiMatrix products in Taiwan, China, and various other countries and, using CombiMatrix CustomArray(TM) Synthesizers in the region, has the ability to synthesize content onto CombiMatrix CustomArrays and to sell those arrays to end customers.

One of the strengths of CombiMatrix's platform is its CustomArray Desktop Synthesizer. CombiMatrix is now establishing manufacturing and distribution relationships with regional companies to enable them to manufacture arrays onsite for their local markets. Such relationships benefit CombiMatrix by expanding the commercial market for its products without having to build additional infrastructure. In addition to sales of synthesizers to the partner, CombiMatrix will continue to sell blank CustomArrays, reagents, additional synthesizers, and equipment to the partner for its local customers. CombiMatrix's partner benefits by gaining access to state-of-the-art microarray technology, which can then be manufactured locally. Other major array manufacturers are not able to execute this business strategy since their manufacturing methods do not enable distributed manufacturing.

“They are an aggressive sales organization, looking to expand their technology base. CombiMatrix sees great opportunity in the areas they serve and sees a great fit with Prisma's expertise.”

"We are very pleased to have Prisma join CombiMatrix's growing international promotion and sales network," said Dr. Amit Kumar, President and CEO of CombiMatrix. "They are an aggressive sales organization, looking to expand their technology base. CombiMatrix sees great opportunity in the areas they serve and sees a great fit with Prisma's expertise."

"Prisma has a great deal of experience especially in the prevalent spotted-array market in Taiwan and China," said Kevin Tseng, President & CEO of Prisma Biotech. "Since we see CombiMatrix's CustomArray technology as the next stage in technological evolution over that technology, we were very interested in the ability to make it available. Users here have been calling out for the next wave. Now that we have it, we begin our work to expand the market and to provide the customers with this new technology."


Prisma Biotech Corporation is a privately held company that was founded in 1995 in Taipei, Taiwan. Prisma has had over ten years of extensive expertise as a vendor and supplier of life-science-research and in vitro-diagnostic (IVD) products in Taiwan. In the area of life-science research, Prisma represents several major brand-name products in genomics and proteomics research, such as arrayers, laser scanners, high-throughput DNA analyzers, protein crystallography machines, automated liquid-handling workstations, and so on. In the area of IVD products, Prisma represents a number of worldwide leading products in lateral-flow technology-related biosensors, raw materials, consumables, accessories, and spotters.

Prisma's unique strength lies in its long-term experience in microarray-related products, which include arraying instruments, parts, accessories, hybridization reagents, and consumables. As a result, Prisma is very familiar with the products, market trends, and channels to the customers in both China and Taiwan.

Prisma is committed to delivering state-of-the-art, quality services and products in order to meet the customer's needs. For further information, contact Prisma at: 7th Floor, 72 Song-Te Road, Taipei 110, Taiwan; Tel: +886-2-27230886, Fax: +886-2-27230876; Website:


Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 42 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.


Acacia Research Corporation
Bret L. Undem (Media Relations), 425-493-2293
Fax: 425-493-2010

Better Be Business Wired.

Business Wire is the leading source for press releases, photos, multimedia and regulatory filings from companies and groups throughout the world.